Vivian Gu, PhD
Postdoctoral Fellow
Research & Publications
Biography
News
Coauthors
Selected Publications
- Thrombocytopathy and endotheliopathy: crucial contributors to COVID-19 thromboinflammation.Gu SX, Tyagi T, Jain K, Gu VW, Lee SH, Hwa JM, Kwan JM, Krause DS, Lee AI, Halene S, Martin KA, Chun HJ, Hwa J. Thrombocytopathy and endotheliopathy: crucial contributors to COVID-19 thromboinflammation. Nature Reviews. Cardiology 2021, 18:194-209.
- AP-2γ Is Required for Maintenance of Multipotent Mammary Stem Cells.Gu VW, Cho E, Thompson DT, Cassady VC, Borcherding N, Koch KE, Wu VT, Lorenzen AW, van der Heide DM, White JR, Kulak MV, Williams T, Zhang W, Weigel RJ. AP-2γ Is Required for Maintenance of Multipotent Mammary Stem Cells. Stem Cell Reports 2021, 16:106-119.
- AP-2α Regulates S-Phase and Is a Marker for Sensitivity to PI3K Inhibitor Buparlisib in Colon Cancer.Beck AC, Cho E, White JR, Paemka L, Li T, Gu VW, Thompson DT, Koch KE, Franke C, Gosse M, Wu VT, Landers SR, Pamatmat AJ, Kulak MV, Weigel RJ. AP-2α Regulates S-Phase and Is a Marker for Sensitivity to PI3K Inhibitor Buparlisib in Colon Cancer. Molecular Cancer Research : MCR 2021, 19:1156-1167.
- TFAP2C regulates carbonic anhydrase XII in human breast cancer.Franke CM, Gu VW, Grimm BG, Cassady VC, White JR, Weigel RJ, Kulak MV. TFAP2C regulates carbonic anhydrase XII in human breast cancer. Oncogene 2020, 39:1290-1301.
- A TFAP2C Gene Signature Is Predictive of Outcome in HER2-Positive Breast Cancer.Wu VT, Kiriazov B, Koch KE, Gu VW, Beck AC, Borcherding N, Li T, Addo P, Wehrspan ZJ, Zhang W, Braun TA, Brown BJ, Band V, Band H, Kulak MV, Weigel RJ. A TFAP2C Gene Signature Is Predictive of Outcome in HER2-Positive Breast Cancer. Molecular Cancer Research : MCR 2020, 18:46-56.
- Targeting the SUMO pathway as a novel treatment for anaplastic thyroid cancer.De Andrade JP, Lorenzen AW, Wu VT, Bogachek MV, Park JM, Gu VW, Sevenich CM, Cassady VC, Beck AC, Kulak MV, Robinson RA, Lal G, Weigel RJ. Targeting the SUMO pathway as a novel treatment for anaplastic thyroid cancer. Oncotarget 2017, 8:114801-114815.
- EGFR Is Regulated by TFAP2C in Luminal Breast Cancer and Is a Target for Vandetanib.De Andrade JP, Park JM, Gu VW, Woodfield GW, Kulak MV, Lorenzen AW, Wu VT, Van Dorin SE, Spanheimer PM, Weigel RJ. EGFR Is Regulated by TFAP2C in Luminal Breast Cancer and Is a Target for Vandetanib. Molecular Cancer Therapeutics 2016, 15:503-11.
- Inhibiting the SUMO Pathway Represses the Cancer Stem Cell Population in Breast and Colorectal Carcinomas.Bogachek MV, Park JM, De Andrade JP, Lorenzen AW, Kulak MV, White JR, Gu VW, Wu VT, Weigel RJ. Inhibiting the SUMO Pathway Represses the Cancer Stem Cell Population in Breast and Colorectal Carcinomas. Stem Cell Reports 2016, 7:1140-1151.
- High TFAP2C/low CD44 expression is associated with an increased rate of pathologic complete response following neoadjuvant chemotherapy in breast cancer.Spanheimer PM, Askeland RW, Kulak MV, Wu T, Weigel RJ. High TFAP2C/low CD44 expression is associated with an increased rate of pathologic complete response following neoadjuvant chemotherapy in breast cancer. The Journal Of Surgical Research 2013, 184:519-25.
- The role of Tcfap2c in tumorigenesis and cancer growth in an activated Neu model of mammary carcinogenesis.Park JM, Wu T, Cyr AR, Woodfield GW, De Andrade JP, Spanheimer PM, Li T, Sugg SL, Lal G, Domann FE, Zhang W, Weigel RJ. The role of Tcfap2c in tumorigenesis and cancer growth in an activated Neu model of mammary carcinogenesis. Oncogene 2015, 34:6105-14.
- A novel animal model for locally advanced breast cancer.Bogachek MV, Park JM, De Andrade JP, Kulak MV, White JR, Wu T, Spanheimer PM, Bair TB, Olivier AK, Weigel RJ. A novel animal model for locally advanced breast cancer. Annals Of Surgical Oncology 2015, 22:866-73.